When it comes to improving diversity and inclusion in clinical trials, while many companies have acted in response to COVID-19 and the way the pandemic highlighted structural deficiencies across the drug-development landscape, the messenger RNA-focused biotech Moderna, Inc. made some notable strides in its vaccine development plan.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?